Hypera S.A. (OTCMKTS:HYPMY) Sees Significant Growth in Short Interest

Hypera S.A. (OTCMKTS:HYPMY) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 2,086,600 shares, an increase of 33,554.8% from the September 30th total of 6,200 shares. Based on an average trading volume of 2,231,900 shares, the short-interest ratio is currently 0.9 days.

Hypera Stock Down 7.4 %

OTCMKTS HYPMY opened at $4.60 on Friday. Hypera has a 1-year low of $3.83 and a 1-year high of $7.90. The stock’s 50 day moving average is $5.06 and its two-hundred day moving average is $5.32.

Hypera (OTCMKTS:HYPMY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.15 EPS for the quarter. The company had revenue of $420.00 million during the quarter.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.